Home/Biosimilar Atlas/Companies/Techdow

Techdow

Biosimilar developer, China. 1 development product across 1 molecule: enoxaparin sodium.

First approval in the Atlas: Sep 2016, Inhixa, enoxaparin sodium (EMA)
FDAproducts approved0
EMAproducts approved1
MHRAproducts approved1
PMDAproducts approved0
HCproducts approved1
CDSCOproducts approved0
EDEproducts registered1
Connections
1molecule1product4 of 7markets0candidates in trials5companies on the same molecules

Portfolio by market

MoleculeProductFDAEMAMHRAPMDAHCCDSCOEDEMarkets
Enoxaparin sodiumInhixa·Sep 2016MHRA·Dec 2020·Jun 20194/7

Month shown is the first approval or registration of that product in that market.

Companies on the same molecules

Developers whose portfolios overlap most with Techdow, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.

BaxterOne shared molecule: enoxaparin sodium2 molecules in its portfolioFresenius KabiOne shared molecule: enoxaparin sodium5 molecules in its portfolioJuno Pharma CanadaOne shared molecule: enoxaparin sodium1 molecule in its portfolioPharmathenOne shared molecule: enoxaparin sodium1 molecule in its portfolioSandozOne shared molecule: enoxaparin sodium10 molecules in its portfolio

Chronology

Compare Techdow with other developers on the comparison page.

Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.

Planning your biosimilar strategy?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.